In this article
Olaratumab FDA Approval and PDGFRα Mechanism
On October 19, 2016, the new drug Olaratumab passed the accelerated approval of the US FDA and could be combined with doxorubicin to treat specific types of soft tissue sarcoma (STS) in adults.
In May this year, FDA granted Olaratumab priority review qualification. Olaratumab was originally designed to block the PDGFRα signaling pathway in cells and microenvironment. In response to this mode of action, Olaratumab also passed the FDA“ breakthrough drug ” , “Fast Track” and “Orphan Drugs” approval.
Olaratumab is a human-derived IgG1 monoclonal antibody that has a high targeting affinity for human platelet-derived growth factor receptor α (PDGFRα). Some studies have found that PDGFRα is found in various tumor tissue Expression, and the abnormal activation of this receptor has a certain relationship with tumors. Preclinical studies believe that PDGFRα may increase tumor proliferation and metastatic potential.
Olaratumab is the first STS initial treatment drug after indosine and radiotherapy were approved more than 40 years ago. For these patients, the most commonly used treatment method was doxorubicin or Combine with other drugs.
Clinical Efficacy and Safety Profile in STS
A clinical trial of 133 patients with metastatic STS containing 25 different tissue types evaluated the efficacy and safety of Olaratumab. The results of the study showed that Olaratumab combined with single-agent adriamycin treatment The survival of the patients in the adriamycin treatment group was significantly improved, with a median overall survival of 14.7 vs 26.5 months; a median progression-free survival of 4.4 vs 8.2 months; and tumor regression rates of 7.5% vs 18.2%, respectively.
Olaratumab treatment has a risk of serious adverse events, including infusion-related reactions and embryo-fetal damage. Infusion-related reactions include hypotension, fever, chills, and rash. The most common treatment side effects are nausea, fatigue, and neutral Granulocytopenia, musculoskeletal pain, mucositis, hair loss, vomiting, diarrhea, loss of appetite, abdominal pain, neuropathy, and headache.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Alysha Mendossa
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.